ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / SBFM / financials
APVO (35) PRFX (34) HCWB (23) SILO (18) ⌘ Pro Terminal β†’

Sunshine Biopharma Inc. (SBFM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.93 -12.01% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.86

Sunshine Biopharma Inc. (SBFM) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (28/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE E β€’ RED ALERT Cap $2.5M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SBFM Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SBFM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Sunshine Biopharma Inc. (NASDAQ: SBFM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $2.93 (-12.01% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SBFM ranks #914 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SBFM compare to APVO and PRFX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SBFM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 33.8%, and ROIC of -21.4%. By comparison, APVO (Aptevo Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and PRFX (PRF Technologies Ltd.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M). Among the 5-stock peer group, SBFM leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SBFM?
β–Ό

Per SBFM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001402328), Sunshine Biopharma Inc. generated $36.3M in revenue (+4.1% YoY), -$6.0M in net income, and -$5.5M in free cash flow against $30.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.86 (-2.35%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 5/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (28/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510028
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D-
Cash (5)Whales (3)SEC (8)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-13.7% Base Target
$487 Bull$3 Base$2 Bear
πŸ“¬ FREE SBFM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SBFM)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
πŸ” WHY SBFM SCORES 28/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) β€’ Piotroski F-Score 4/9

β–² #2 Bullish Driver: Macro Regime Fit+7/20 pts (25% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 29.9 (OVERSOLD (<32))

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
36
Grade E$6.04-19.9% Next Q
Q2 (-2Q)
33
Grade E$4.84-45.2% Next Q
Q3 (-1Q)
31
Grade E$2.65+10.6% Next Q
Current
28
Grade E$2.93-10% Hist 90D Ξ±
Trajectory: E (36) β†’ E (28)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a SBFM Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While SBFM currently carries a cautious 28/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.76) and Max Pain ($3.08) forces dealer call-delta covering toward $487.20.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SBFMβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSBFM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How SBFM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$36.3MGross Profit $12.3M (33.8%)Cost of Sales $24.1MOp Profit $0 (0%)OpEx (R&D/SG&A) $12.3MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $24.1M
FY24
Rev $34.9M
FY25
Rev $36.3M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$36.3M33.8%-17.2%-$6.0M-$5.5M-21.4%
FY 2024$34.9M30.6%-16.7%-$5.1M-$14.2M-19.5%
FY 2023$24.1M33.8%-19.9%-$4.5M-$8.8M-21.4%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SBFM)

  • βœ“Walkthrough of SBFM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
SBFM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -98.67%⚑ TESTING RESISTANCE
2026-11-02O $3.11H $3.33L $2.93C $2.93VOL 183.4K
RES: $34.30SUP: $0.48SMA50: $13.76SMA200: $107.9
$496.3$362.5$228.7$94.86$-38.95RES $34.30SUP $0.48$2.932026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SBFM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ SBFM Butterfly Map β†’ + Track SBFM β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +4.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SBFM today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SBFM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SBFM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SBFM)

Health Care Rank #914 of 1016 βš”οΈ APVO vs SBFM Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (SBFM vs. APVO, PRFX, HCWB, SILO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sunshine Biopharma Inc. (SBFM) ranks #914 by composite RQD confidence (28/100, grade E) and #986 by equity capitalization ($2.5M). Within this direct 5-issuer industry benchmark cohort, SBFM leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. APVO currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with SBFM at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SBFM ACTIVE
Sunshine Biopharma Inc.
E 28/100 β€” 33.8% -21.4% -12.01% $2.5M Benchmark Subject
APVO
Aptevo Therapeutics Inc.
D- 35/100 β€” β€” -35.0% -1.47% $2.5M /apvo-vs-sbfm β†’
PRFX
PRF Technologies Ltd.
E 34/100 β€” -30.0% -35.0% -2.68% $2.6M /prfx-vs-sbfm β†’
HCWB
HCW Biologics Inc.
E 23/100 β€” 20.0% -35.0% -6.78% $2.6M /hcwb-vs-sbfm β†’
SILO
Silo Pharma Inc.
E 18/100 β€” 38.6% -35.0% -1.60% $2.4M /silo-vs-sbfm β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001402328

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sunshine Biopharma Inc. (SBFM) reported GAAP revenue of $36.3M (+4.1% vs. FY2024 revenue of $34.9M , and +50.7% cumulative change since FY2023) , GAAP net income of -$6.0M, operating cash flow of -$5.3M, and free cash flow of -$5.5M (+61.2% YoY). On the balance sheet, SBFM closed FY2025 with $30.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $36.3M -$6.0M -$5.3M -$5.5M $30.1M β€”
FY2024 (FY) 2024-12-31 $34.9M -$5.1M -$12.5M -$14.2M $30.6M β€”
FY2023 (FY) 2023-12-31 $24.1M -$4.5M -$8.8M -$8.8M β€” β€”

3. SBFM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SBFM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Sunshine Biopharma Inc. (NASDAQ: SBFM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $2.93 (-12.01% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SBFM ranks #914 in composite RQD confidence.

How does SBFM compare to APVO and PRFX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SBFM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 33.8%, and ROIC of -21.4%. By comparison, APVO (Aptevo Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and PRFX (PRF Technologies Ltd.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M). Among the 5-stock peer group, SBFM leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SBFM?

Per SBFM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001402328), Sunshine Biopharma Inc. generated $36.3M in revenue (+4.1% YoY), -$6.0M in net income, and -$5.5M in free cash flow against $30.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SBFM trading relative to its 50-day, 200-day, and 52-week technical levels?

SBFM last traded at $2.93 (-12.01% on volume of 114,235 shares), positioning the stock -78.71% below its 50-day simple moving average ($13.76) and -97.28% below its 200-day simple moving average ($107.85). Across its 52-week range of $2.58 to $464.00, SBFM sits at the 0.1% percentile with a 14-day RSI of 29.9 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($2.56 to $3.30).

SBFM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

How profitable is Sunshine Biopharma Inc. (SBFM)?

In FY 2025 (10-K), SBFM converted $36.3M of revenue into a 33.8% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: SBFM RQD Cockpit SBFM 12M Forecast SBFM Earnings & Move SBFM Dividends & DRIP SBFM Insiders & 13F SBFM Whale Options SBFM Profit Sankey SBFM News & Why
ROARABLE RATING BRIEF β€’ RQD 28/100 (E) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

SBFM β€” Sunshine Biopharma Inc.: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline
As of: 2026-11-02T14:57Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Sunshine Biopharma Inc. (SBFM) carries a composite score of 28/100 (E β€” Roarable Strong Sell β€” Forensic Risk / Avoid) at a current price of $2.93 (-12.01%). Fundamental cash generation scores 5/20 (ROIC -21.4%, FCF yield β€”), institutional 13F whale accumulation scores 3/20, insider conviction scores 5/20, macro regime alignment scores 7/20 (Beta 1.00), and forensic balance-sheet protection scores 8/20 (Altman Z-Score 0.20, Piotroski F-Score 4/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (-17.2%) and free cash flow conversion relative to the 52-week range of $2.58 – $464.00.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), SBFM is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin 33.8%), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

SBFM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sunshine Biopharma Inc. (SBFM) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to SBFM Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SBFM Bull vs. Bear Conversation Board β€” What's Your Call at $2.93?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SBFM 🐻 67% BEARISH CONVICTION
1. Pick Your Side on SBFM:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.93 (-12.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is SBFM (E β€’ RQD 28/100) a Buy at $3.33?

Welcome to the SBFM (Sunshine Biopharma Inc.) Roar Pit. Current RQD Composite is 28/100 (Roarable Strong Sell β€” Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.66 (-20.1%)
Spot @ $3.33

Pump the brakes on SBFM β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SBFM, but look at what you are paying: current EV/EBITDA multiples with 33.8% gross margins. Unless Sunshine Biopharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $4.10 (+23.1%)
Spot @ $3.33

SBFM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SBFM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.33 (52-wk range $2.58 - $464.00), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%